PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23916291-0	2013	A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.	phyllodes	22-31	cyclin dependent kinase inhibitor 2A	Homo sapiens	69-72	
23916291-2	2013	Here, we systematically study p16 and Rb expression in 34 phyllodes tumors in relation to proliferation.	phyllodes	58-67	cyclin dependent kinase inhibitor 2A	Homo sapiens	30-33	
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	69-72	
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	123-126	
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	123-126	
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	123-126	
23916291-13	2013	Ki-67 was highest in malignant phyllodes with diffuse p16+/Rb- labeling.	phyllodes	31-40	cyclin dependent kinase inhibitor 2A	Homo sapiens	54-57	
23916291-14	2013	In summary, 50% malignant phyllodes display evidence of Rb/p16 pathway alterations, likely reflecting p16 or Rb inactivation.	phyllodes	26-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	59-62	
23916291-14	2013	In summary, 50% malignant phyllodes display evidence of Rb/p16 pathway alterations, likely reflecting p16 or Rb inactivation.	phyllodes	26-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	102-105	
20497245-0	2010	p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours.	phyllodes	93-102	cyclin dependent kinase inhibitor 2A	Homo sapiens	0-3